We have examined the effect of the ribonucleotide reductase inhibitors thymidine (dThd) and hydroxyurea (HU) on the metabolism and cytotoxicity of high concentrations (10 to 100 pmol/L) of cytosine arabinoside (Ara-C) in a deoxycytidine kinase-deficient, highly Ara-C-resistant human promyelocytic leukemic cell subline (HL-GO/Ara-C). Administration of dThd or HU (0.5 to 3 mmol/L) in conjunction with high concentrations of Ara-C either sequentially or simultaneously lead to enhanced (and in some cases a supraadditive) inhibition of HL-GO/Ara-C suspension culture growth and soft agar colony formation. In addition, exposure of cells to 0.5 mmol/L dThd or HU for 48 hours significantly in-
C the treatment of acute leukemia in humans.' Intracellularly, Ara-C is converted to its monophosphate derivative, Ara-CMP, by the pyrimidine salvage pathway enzyme deoxycytidine kinase (dCK)'; this process represents the rate-limiting step in Ara-C metab~lism.~ Ara-C is converted ultimately to its lethal triphosphate derivative, Ara-CTP, which is an inhibitor of DNA polymerase4 and is incorporated into elongating DNA strands? Ara-C is an S-phasespecific agent and Ara-C DNA incorporation may be the primary mode of Ara-C-mediated lethality toward human leukemic c e k 6 Deoxycytidine triphosphate (dCTP) serves as a negative feedback regulator of dCK: and is also capable of antagonizing Ara-CTP DNA incorporation and inhibition of DNA p~lymerase.~ Consequently, reductions in intracellular levels of dCTP might logically be expected to augment Ara-C metabolism and cytotoxicity. For example, the nucleoside thymidine (dThd), whose triphosphate derivative dTTP inhibits the enzyme ribonucleotide reductase and stimulates dCK,' has been shown to potentiate Ara-C nucleotide formation and lethal effects in several experimental tumor Similarly, the agent hydroxyurea (HU), which inhibits an alternate subunit of ribonucleotide reductase," has been found to augment Ara-C phosphorylation and toxicity in murine and human leukemic cells.12 Based in part on these studies, clinical trials involving administration of thymidine or hydroxyurea in conjunction with standard dose Ara-C have been initiated in patients with refractory leukemias and lymphomas. [13] [14] [15] Previous preclinical studies examining the interaction of pyrimidine antagonist such as thymidine or hydroxyurea with Ara-C have generally used sensitive cell lines and have used relatively low concentrations of Ara-C (eg, 1 pmol/L or le~s)~,'~.'' reflecting steady-state plasma Ara-C levels in patients receiving conventional dose Ara-C therapy (eg, 100 to 200 mg/m'/d).l8 Recent experience with high-dose Ara-C regimens has established the feasibility of administering doses as high as 3 g/mZ by bolus injection over 1 to 3 hours, yielding peak plasma Ara-C levels in excess of 100 kmol/ L.I9 In a phase I study of continuously administered Ara-C in patients with solid tumors, 250 mg/mz/h resulted in steady-state plasma Ara-C concentrations of 10 to 59 creased the percentage of HL-6O/Ara-C in S-phase. In contrast to previous studies involving low-dose Ara-C administration, we were unable to detect dThd-or HU-mediated increments in Ara-CTP formation in HL-GO/Ara-C cells treated with high-dose Ara-C despite reductions in intracellular dCTP pools as great as 65%. However, dThd or HU did increase Ara-C incorporation into newly synthesized DNA. These studies show that administration of dThd or HU in conjunction with high concentrations of Ara-C results in an enhanced antiproliferative effect of Ara-C against Ara-C-resistant leukemic cells deficient in deoxycytidine kinase.
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kmol/L." There is presently little information available concerning the interaction of HU or dThd and Ara-C in drug-resistant cells, or the effect of these pyrimidine antagonists on the metabolism and cytotoxicity of Ara-C when the latter is administered at concentrations now achievable with high-dose regimens.
Resistance to Ara-C in acute myeloid leukemia (AML) cells has been attributed to cytokinetic factors as well as reduced intracellular metabolism of Ara-C.21-23 Although decreased activity of dCK and consequently reduced Ara-CTP formation is not the sole biochemical mechanism of refractoriness to Ara-C, several studies have shown that clinical resistance to Ara-C is frequently accompanied by low dCK activity?626 Our group has previously isolated a dCK-deficient, highly Ara-C-resistant human promyelocytic leukemic subline (HL-60/Ara-C) that is capable of proliferating in the presence of Ara-C concentration exceeding 1 k m~l / L .~~ In contrast, the parental HL-60 line exhibits an Ara-C IC,, of approximately 5 nmol/L. HL-60/Ara-C cells exhibit significantly reduced Ara-CTP generation and retention as well as markedly decreased Ara-C DNA inc~rporation.'~ The present studies were undertaken to determine whether dThd-or HU-mediated deoxyribonucleotide perturbations could potentiate the metabolism and cytotoxicity of higher concentrations (eg, 10 pmol/L) of Ara-C in these cells, thereby circumventing resistance.
Intracellular dCTP levels. The effect of HU and dThd on intracellular dCTP pools in HL-60/Ara-C was determined using minor modification^^^ of a previously described DNA polymerase assay.'" Cells (cell density, 5 X lo4 cellsiml) were placed in T-flasks containing various concentrations of dThd or HU and placed in the 37"C, 5% CO, incubator for 6 hours. At the end of this period, the cells were transferred to precooled centrifuge tubes, pelleted at 4"C, and methanol extracts of the cell pellet were obtained.8 The extracts were then evaporated to dryness using a table top lyophilizer. The method for quantitating dCTP was based on the incorporation of ['HI dCTP onto a synthetic copolymer of poly-dldC in the presence of luteus DNA polymerase, and has been described previously."' Standard amounts of dCTP were quantitated in conjunction with each assay, and values for each condition were expressed as picomoles of dCTP per 10' cells.
Logarithmically growing cells were incubated with dThd or HU for 6 hours, as described in the previous section. They were then washed free of drug, resuspended in RPMI medium containing 10% FCS at a cell density of 5 x lo5 cells/mL in 25-cm2 T-flasks, and incubated for 4 hours in the presence of 10 pmol/L ['HI Ara-C (final specific activity, 0.8 Ci/mmol) at 37°C and 5% CO,. At the end of the incubation period, the cells were pelleted, washed twice with cold phosphate-buffered saline (PBS), and DNA isolated and purified by pronase and RNAse digestion, phenol chloroform extraction, and ethanol precipitation as previously described.' After centrifugation at 9,OOOg at 4°C for 30 minutes, the DNA was resuspended Drugs and chemicals.
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in Tris-HC1 buffer, quantitated spectrophotometrically, and aliquots removed and placed in scintillation vials and radioactivity determined. Values for each condition are expressed as picomoles of Ara-C per micrograms of DNA.
In some experiments, cells were simultaneously incubated with 10 pCi/mL "P (Amersham) and the amount of [32P]-incorporated DNA monitored as an indicator of new DNA synthesis." The amount of Ara-C incorporated into newly synthesized DNA for each condition was determined by normalizing values obtained to reflect the relative rates of new DNA synthesis.
The effect of dThd and HU on the cell cycle traverse of HL-60IAra-C was studied using an Epics V flow cytometer (Coulter Electronics, Hieleah, FL)." Cells were incubated for periods of 6 to 48 hours with various concentrations of dThd or HU at 37°C and 5% CO,. At the end of this period, cells were centrifuged at 1,200g for 8 minutes at room temperature, and the supernatants discarded. The cell pellets were resuspended in a solution containing 50 kg/mL propidium iodide in 0.1 mol/L Tris (pH 7), incubated at 37°C for 2 hours, and subsequently stored at 4°C before analysis. Under these conditions, samples remain stable for at least 2 weeks. Histograms of 50,000 cells were obtained with an Epics V flow cytometer using a 488-mm Argon ion laser line to induce fluorescence. Ten-micrometer diameter 114 bright fluorospheres (Coulter) were used to standardize fluorescence intensity. DNA content distribution histograms were recorded on an X-Y recorder and analyzed by the Epics B integration routine using user setting channel limits to yield the percentage of the cell population in GI-, S-, and G,-phases.
Logarithmically growing HL-60/Ara-C cells were exposed to dThd or HU for 6 hours, washed with fresh medium to remove drug, and resuspended in T-flasks containing Ara-C for an additional 18 hours. Alternatively, cells were exposed to Ara-C and dThd or HU for the same intervals in the reverse sequence. At the end of the 24-hour period, cells were washed free of drug, the cell density adjusted to lo5 cells/mL with drug-free media, and 5-mL aliquots transferred to T-flasks, which were maintained in an incubator for 72 hours. In simultaneous exposure studies, cells were incubated for 24 hours in the presence of Ara-C and either dThd or HU, washed free of drug, and seeded in T-flasks as above for 72 hours. Finally, in some studies cells were seeded in T-flasks in the presence of Ara-C and dThd or HU for the entire 72-hour incubation period. Aliquots were then removed for cell counts. Under these conditions, control cells undergo approximately three to four doublings and reach a cell density of about 10' cell/mL. Growth inhibition for each experimental condition was determined by comparing the increment in cell density for that condition at 72 hours with that observed for untreated control cells.
Logarithmically growing HL-60/ Ara-C cells were exposed simultaneously or sequentially to dThd or HU and Ara-C in the same manner as in the previous section. After washing cells free of drug, they were resuspended in a fresh medium and 2,000 cells/condition plated in soft agar using a standard bilayer agar system. 27 In some experiments, cells were plated in the continuous presence of Ara-C in conjunction with dThd or HU. Colonies consisting of groups of 50 or more cells were scored. Inhibition of colony formation for each condition was determined in the same manner as described for suspension culture growth. Characterization of drug interactions with respect to the survival fraction of drug treated cells (ie, additive, subadditive, or antagonistic) was based on previously published criteria for the in vitro evaluation of combination ~hemotherapy.'~ The interaction of continuously administered dThd or HU and Ara-C in relation to suspension culture and soft agar growth of HL-60IAra-C was analyzed through isobolo-
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For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Logarithmically growing HL-6O/Ara-C cells were incubated with 0.5 to 3 mmol/L dThd or HU in the presence or absence of 100 pmol/L Ara-C for 24 hours. At the end of this period, cells were washed thoroughly to remove drug and either plated in soft agar for 8 days or grown in suspension culture for 72 hours, as described in Materials and Methods. Values were expressed as the percentage of control cell colony formation or suspension culture growth (shown in parentheses), and represent the means for duplicate experiments performed on at least three seDarate occasions f 1 SD.
gram analysis." Cells were grown in the presence of various concentrations of h a -C . At each level the concentration of dThd or HU necessary to achieve a 100% inhibition of suspension culture growth or colony formation was determined. The shape o f the curves generated were then compared with a theoretical straight line intersecting the X and Y axes representing an additive interaction as previously described."
Significant differences between experimental groups were assessed using Student's t-test for paired observation.
Statistical analysis.
RESULTS
The effect of 24 hours of simultaneous exposure to 100 pmol/L Ara-C with and without dThd or HU on the clonogenicity and suspension culture growth of HL-60/ Ara-C is shown in Table 1 . When Ara-C was administered alone for this period, only 5% reduction of either colony formation or suspension culture growth was noted. Coadministration of dThd or HU at concentrations reducing colony formation by 17% to 73% resulted in a supraadditive decline in growth. For example, the survival fraction of HL-60/Ara-C exposed to 3 mmol/L dThd was 39%, to 100 pmol/L Ara-C, 94%, and to the two drugs together, 21%. The expected survival fraction, assuming an additive interaction between the two drugs, would be 37%. Corresponding values for 0.5 mmol/L HU were: expected survival (additive interaction), 45%; actual survival fraction, 28%. The pattern of suspension culture growth inhibition by Ara-C and dThd or HU closely followed that observed for any of the dThd or HU dose levels tested.
The effect of continuous exposure of HL-60/Ara-C cells to Ara-C in conjunction with dThd or HU is shown in Table  2 . Coadministration of dThd or HU alone with 10 or 50 pmol/L Ara-C for the entire 8 days of incubation in the case of cloning studies, or 72 hours in suspension culture growth studies, resulted in further inhibition of HL-60/ h a -C cell growth. For example, colony formation was 43.5% of control for 50 pmol/L dThd alone, 37.8% for 50 pmol/L Ara-C alone, and 7.3% for both agents together. Corresponding values for hydroxyurea were: 50 pmol/L HU alone, 55.2%; HU in conjunction with 50 pmol/L Ara-C, 10.4%. As in the case of 24 hours of exposure to drugs, the pattern for suspension culture growth inhibition closely paralleled that observed for colony formation. To determine the effect of drug sequence on antiproliferative response, HL-60/Ara-C were exposed to dThd or HU for 6 hours either before or after 18 hours of exposure to 100 pmol/L Ara-C (Fig 1) . Cells exposed to Ara-C or dThd alone exhibited 96% f 9% and 83% 2 8% of control colony formation, respectively, whereas cells exposed sequentially to dThd followed by Ara-C exhibited 50% f 11% of control growth. However, sequential administration of Ara-C followed by dThd resulted in an even greater decline in colony formation (38% & 13%), although this difference was not statistically significant (P > .OS). The same pattern was observed for HU (Fig 1) . Cells exposed to 3 mmol/L HU exhibited 64% f 14% of control colony formation, whereas cells exposed to HU followed by Ara-C exhibited 32% f 7% of control growth. The reverse sequence of drug administration (Ara-C followed by HU) resulted in only 25% f 6% of control colony formation, but, again, this difference was not statistically significant. A similar pattern of drug response was observed with respect Logarithmically growing HL-6O/Ara-C cells were simultaneously exposed to 10 to 50 pmol/L dThd or HU and 10 or 50 pmol/L Ara-C for 8 days (cloning studies) or 72 hours (suspension culture growth studies) as described in Materials and Methods. Values were expressed as the percentage of drug-treated cell colony formation or suspension culture growth (shown in parentheses) relative to untreated controls, and represent the means for at least three separate experiments performed in duplicate f 1 SD.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Logarithmically growing HL-GO/Ara-C cells were exposed t o 3.0 mmol/L dThd or HU for 6 hours, washed, and incubated with 100 qnol/LAra-Cfor 18 hours. Alternatively, cells were exposed t o Ara-C for 18 hours before 6 hours of exposure t o dThd or HU. Cells were then washed repetitively t o remove all drug and either plated in soft agar for 8 days or grown in suspension culture for 72 hours. Values are expressed as a percentage of control cell tion ( 0 ) or suspension culture growth sent the means for duplicate experime Ara.C to the suspension culture growth of HL-60/Ara-C cells, except that administration of dThd followed by Ara-C resulted in a slightly greater inhibitory effect than the reverse sequence.
To analyze further the interaction of continuously administered dThd or HU and Ara-C with respect to the clonogenicity and suspension culture growth of HL-60/ Ara-C, isobologram analysis was used (Fig 2) . Cells were exposed to various concentrations of Ara-C in conjunction with a concentration of dThd or HU necessary to produce 100% inhibition of colony formation (or suspension culture growth). A plot of dThd or HU versus Ara-C concentrations yielded a concave-shaped curve in both cases, suggesting a synergistic interaction (Fig 2) . Similarly shaped curves were generated when other endpoints (eg, 50% inhibition of growth) were used (data not shown).
The data in Table 3 illustrate the effect of 6 hours of pretreatment with dThd or HU on the 2-hour intracellular accumulation of Ara-CTP in HL-60/Ara-C cells. In general, exposure of cells to either dThd or HU had a small effect on the formation of Ara-CTP at each Ara-C dose level (10 to 100 pmol/L), and in some cases actually resulted in a decline in the Ara-CTP formation. For example, exposure of cells to 3 mmol/L dThd followed by 2 hours of exposure to 100 p,mol/L Ara-C resulted in an intracellular accumulation of 38.9 f 9.4 pmol Ara-CTP compared with 48.4 t-13.4 for control cells. This difference did not achieve statistical significance (P > .05). Similarly, pretreatment of cells with lower concentrations of dThd or exposure to lower concentrations of Ara-C (eg, 10 pmol/L or 50 pmol/L) also did not result in significant differences in intracellular Ara-CTP accumulation at 2 hours. Pretreatment of cells with HU resulted in small increases in the 2-hour formation of Ara-CTP, but, again, differences between drug-treated and control cells were not significant (P > .05). In no instance did dThd or HU pretreatment or coadministration produce a statistically significant increment in Ara-CTP intracellular accumulation at any of the Ara-C concentrations studied.
Ara-CTP formation and Ara-C (DNA) was quantitated in cells exposed to dThd or HU for 6 hours followed by 10 pmol/L Ara-C for 4 hours ( Table 3) . For both dThd and HU, preincubation with drug did not significantly alter the amount of Ara-C incorporated into DNA (P > .05). However, when corrections were made to reflect the relative rates of DNA synthesis (as determined by 3zP incorporation), increments in DNA incorporation in drug-treated specimens ranged from 40% to 87% ( Table 3) . Additional For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Logarithmically growing HL-6O/Ara-C cells were exposed to the designated concentrations of dThd or HU for 6 hoursfollowed by exposure to 10 to 100 pmol/L Ara-C for an additional 2 hours. Intracellular levels of Ara-CTP were determined as described in Materials and Methods. Values were expressed as pmol Ara-CTP/106 and represent the means for at least three experiments performed in duplicate +1 SD. For DNA incorporation studies, cells were exposed to 10 DNA and represent the means for duplicate experiments performed on three separate occations. Values in parentheses are corrected for rates of DNA synthesis as determined by "P incorporation.
Abbreviation: ND, not done.
experiments were performed to determine whether preincubation with dThd or HU was capable of producing intracellular dCTP pool perturbations in HL-60/Ara-C cells (Table   4 ). Six hours of exposure to 0.5 mmol/L and 3 mmol/L dThd reduced dCTP levels to 64% and 38% of control values, respectively. Incubation of cells with HU resulted in smaller decreases in dCTP levels (14% and 23% reductions for 0.5 mmol/L and 3 mmol/L, respectively). These findings suggest that while HU-and dThd-mediated reductions in dCTP pools may not result in an increase in the total amount of Ara-C DNA incorporation, they may increase the concentration of Ara-C residues incorporated into newly synthesized DNA.
An analysis of dThd-and HU-mediated perturbations in the cell cycle traverse HL-60/Ara-C cells is shown in Table  5 . Cells were exposed to lower concentrations of dThd or HU (50 kmol/L to 0.5 mmol/L) because higher concentrations were associated with extensive cell death and fragmentation and unevaluable DNA histograms. Exposure of cells to dThd and HU resulted in a decrease in the percentage of cells in GI-phase and an increase in S-phase; this effect was more pronounced with higher drug concentrations and a longer (48-hour) exposure interval. For example, the per- Logarithmically growing HL-6O/Ara-C cells were incubated in the presence of the designated concentrations of HU or dThd for 6 hours in a 37°C. 5% C 0 2 incubator. Methanol extracts of the cell pellet were then obtained, lyophilized, and dCTP concentrations determined using the DNA polymerase assay. Values were expressed as pmol dCTP/106 cells and represent the means for duplicate experiments performed on at least three separate occasions f 1 SD.
centage of S-phase cells (relative to controls) at 48 hours increased by 86% and 62% after exposure to 0.5 mmol/L dThd and HU, respectively.
DISCUSSION
The mechanism(s) by which the ribonucleotide reductase inhibitors HU and dThd potentiate the cytotoxicity of Ara-C in neoplastic cells remain incompletely understood. Cell cycle distribution of HL-6O/Ara-C cells exposed to dThd or HU. Logarithmically growing cells were exposed to 50 to 100 pmol/L dThd or HU for 24 and 48 hours after which DNA histograms were obtained using a Coulter Epics IV Flow Cytometer. The number of cells in G,-, S,-, or G,-M-phase were determined by user set channel limits and expressed as a percentage of the total cell population. Values represent the means for at least three separate experiments; standard deviations were generally less than 10% of the means.
HU (pmol/L)
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Although the dThd-mediated depletion of intracellular dCTP pools resulting in enhanced dCK activity and increased Ara-C phosphorylation has been postulated to account for this intera~tion,~~" other factors are likely to be involved. For example, dTTP is known to stimulate the activity of dCyd kinase directly and inhibit deoxycytidylate deaminase, and consequently dThd may stimulate Ara-CTF' formation independent of dCTP pool perturbation^.^^
In the case of HU, dCTP pool reduction cannot be the sole explanation for this phenomenon, because some observers have reported either no change or actually small increments in intracellular dCTP levels in cells exposed to HU.35 However, in several previous studies in which dThd or HU have been reported to potentiate Ara-C cytotoxicity at concentrations of 10 p,mol/L or less, enhancement of Ara-C activation has been ~b s e r v e d .~~'~~'~ More recently, Robichaud and Fram reported that HU increased the cytotoxicity and DNA incorporation of Ara-C administered over brief intervals (eg, 3 hours) in the Lo Vo colon carcinoma line,3h although Ara-CTP and dCTP levels were not determined in this study. Finally, Kubota et al found that pretreatment of HL-60 but not CEM cells with 1 mmol/L HU resulted in a reduction in dCTP levels and greater than twofold increments in Ara-CTP formation when Ara-C was administered at concentrations of 10 p,mol/L or less, which resulted in an enhanced cytotoxicity for the drug ~ombination.3~ These investigators also reported that HU did not significantly increase Ara-CTP formation or Ara-C-mediated cytotoxicity despite a reduction in dCTP levels in the human T-lymphoblastic CEM cells. In contrast to these findings, we were unable to detect increases in Ara-CTP formation in HL-60/Ara-C cells exposed to high (eg, 10 to 100 kmol/L) concentrations of Ara-C in conjunction with dThd or HU, despite enhanced, and in some cases supra-additive, antiproliferative effects for the drug combination. The failure to augment Ara-CTP formation occurred despite substantial reductions in dCTP levels and was observed in cells exposed to Ara-C for both short (2 hours) and long (24 hours) intervals. A potential explanation for our findings may be related to the kinetic characteristics of the rate-limiting enzyme dCyd kinase, which has been reported to exhibit a Km of 20 kmol/L with respect to Ara-C in human leukemic cells.38 It is possible that when Ara-C is administered at levels at or exceeding the Km for this enzyme, increments in enzyme activity may have a minor effect on Ara-CTP formation. These observations are in accord with previous studies by Harris and Smith,3' who examined Ara-CTP formation in patientderived human leukemic myeloblasts exposed to various concentrations of Ara-C. They found that Ara-C concentrations in excess of 10 pmol/L resulted in little enhancement of Ara-CTP intracellular acc~mulation.~~ In addition to their failure to enhance Ara-CTP formation in HL-60/Ara-C cells, dThd and HU were incapable of increasing total Ara-C DNA incorporation despite reducing intracellular dCTP levels by as much as 65%. Because dCTP competes with Ara-CTP for binding to the enzyme DNA polymerase,40 reduction in dCTP levels would ordinarily be expected to augment Ara-C DNA incorporation. However, Howell et al previously showed that dThd and HU reduced the incorporation of Ara-C into the DNA of sensitive HL-60 cells per unit time, presumably by reducing rates of DNA synthesis.'6 When corrections were subsequently made to reflect incorporation of Ara-C into newly synthesized DNA, values were substantially higher for dThd-and HU-treated cells. Our findings show that a similar phenomenon occurs when high concentrations of Ara-C are administered to resistant cells, because HU and dThd both increased Ara-C incorporation when corrections for DNA synthetic rates were taken into account. This enhancement might contribute to the supra-additive growth inhibitory effects observed when HU and dThd were combined with Ara-C in these cells. Because the conditions for the exposure to these drugs were not identical in the growth inhibition and Ara-C DNA incorporation studies, we could not make a direct correlation between Ara-Cmediated cytotoxicity and Ara-C DNA incorporation, as shown by Kufe et a1 in human leukemic c e k 6
Because dThd-and HU-mediated enhancement of highdose Ara-C metabolism may not entirely explain the interaction between these agents, other factors might be considered. For example, Ara-C is an S-phase-specific agent, and only cells actively engaged in DNA synthesis are vulnerable to its
It has been previously shown that exposure of sensitive HL-60 cells to HU or dThd for prolonged periods resulted in an accumulation of cells in S-phase where they were susceptible to the lethal effects of Ara-C." We also found that HL-60/Ara-C cells exposed to dThd or HU exhibit a higher percentage of S-phase cells, raising the possibility that cell synchronization may contribute to the drug interaction. In addition to these cytokinetic considerations, interactions between dThd or HU and Ara-C at other biochemical levels have been documented, including inhibition of DNA repair:* deactivation of deoxycytidylate deaminase,43 and inhibition of glycolipid and glycoprotein synthesis." Recently, high concentrations of Ara-C have been shown to markedly reduce the expression of the growth-related proto-oncogene c-myc,4s which is known to be amplified in circular extrachromosomal DNA (episomes) or in double minutes.& HU is known to increase the loss of unstably amplified genes, including those mediating drug r e s i s t a n~e .~~ This may be one of the molecular mechanisms by which HU might enhance the growth inhibitory effects of Ara-C. It is therefore possible that the interaction of these pyrimidine antagonists and Ara-C is multifactorial, making a single mechanism underlying enhanced cytotoxicity unlikely.
The finding that administration of dThd or HU in conjunction with high concentrations of Ara-C effectively inhibits the growth of highly Ara-C-resistant human leukemic cells has implications for the design of clinical regimens. However, the efficacy of such regimens will depend on a variety of factors that cannot be assessed in in vitro studies. For example, while the possibility of administering high doses of dThd (eg, 30 g/m2/d) or HU ( 2 g/m2/d) in conjunction with conventional dose Ara-C (eg, 100 to 200
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
